Association between the rs1042522 polymorphism in <i>TP53</i> and prostate cancer risk: An updated meta‐analysis

Fan, Song; Hao, Zongyao; Zhang, Meng; Liang, Chaozhao

doi:10.1016/j.cdtm.2017.04.001

Cited by 6 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found the 7676154C>G (rs1042522) mutation in the 4 th exon. This mutation has been previously associated with some cancers (Chen et al, 2015; Huang et al, 2019) but not with PC (Fan et al, 2017). Also, our study showed that this mutation is inherited and is in both BPH and healthy groups in a similar frequency, which proves this is not a risk factor for the development of BPH.…”

Section: Discussionmentioning

confidence: 91%

Changes in TP53 gene, telomere length, mitochondrial DNA, and its amount in benign prostatic hyperplasia patients

Zole,

Baumanis,

Freimane

et al. 2024

Preprint

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a growing issue due to an ageing population; however, there are not enough studies connecting it with ageing hallmarks. Some of the ageing hallmarks are changes in telomere length (TL) and genetic changes like possible mutations in the TP53 gene or mitochondrial genome (mtDNA). Our study investigated these factors to see if they could be linked with BPH. Prostate tissue samples were obtained from 32 patients with BPH (and 30 blood samples). As a healthy control group, age-matching blood DNA samples were used. For mtDNA sequence data comparison, 50 samples of a general Latvian population were used. The full mtDNA genome was sequenced using Next Generation Sequencing (NGS), for TP53 gene - Sanger sequencing, and for mtDNA amount and telomere length - qPCR assay. BPH patients in prostate tissue had much higher TL than in blood cells, and the healthy controls had the shortest telomeres. Also, the mtDNA amount in BPH prostate tissue was the highest compared with blood, and controls had the smallest amount. In the TP53 gene, we did not find any mutations that could be linked to BPH. In the mtDNA genome, we found several unique mutations and heteroplasmic changes, as well as changes that have been linked before with prostate cancer (PC). In conclusion, prolonged telomeres and changes in mtDNA amount might be involved in the development of BPH. Concerning mtDNA genome changes, some of the heteroplasmic or homoplasmic variants might contribute to the development of BPH. More studies should be conducted to prove or disapprove of these connections.

show abstract

Section: Discussionmentioning

confidence: 91%

Changes in TP53 gene, telomere length, mitochondrial DNA, and its amount in benign prostatic hyperplasia patients

Zole,

Baumanis,

Freimane

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“… 11 Protein phosphorylation occurs mainly in two amino acids: serine (including threonine), and tyrosine. 11 Gene polymorphisms that create, alter, or destroy phosphorylation sites have been recognized as functional variants for human diseases, such as prostate cancer (TP53 rs1042522) 12 and tuberculosis (TLR2 rs5743708). 13 Niu et al found that IDUA phosphorylation-related SNPs rs3755955 and rs6831280 exert indirect effects on nearby phosphorylation sites, which could affect the risk of OP.…”

Section: Discussionmentioning

confidence: 99%

IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis

Lin

et al. 2021

PGPM

View full text Add to dashboard Cite

Alpha-L-iduronidase (IDUA) rs3755955 and rs6831280 polymorphisms have been demonstrated to be associated with bone mineral density (BMD). However, no study has investigated the association of these two polymorphisms with osteoporosis (OP) susceptibility in Chinese postmenopausal women. Patients and Methods: IDUA gene polymorphisms were genotyped in 278 women with OP and 303 healthy controls via polymerase chain reaction and Sanger sequencing. Results: Our data indicated that IDUA rs3755955 and rs6831280 polymorphisms increased the risk of OP in homozygous, dominant, and allelic models. We observed lower lumbar spine BMD in younger women with the AA genotype of rs3755955 polymorphism. Finally, mutant genotypes with rs6831280 polymorphism were more sensitive to zoledronic acid treatment, and the treatment effect was significant in terms of BMD levels. Conclusion:In conclusion, IDUA rs3755955 and rs6831280 polymorphisms demonstrated susceptibility to OP in Chinese postmenopausal women. IDUA rs6831280 polymorphism caused differences in response to zoledronic acid treatment.

show abstract

“…And the results showed no association between TP53 polymorphism and prostate cancer risk, which was consistent with a previous study. [19] However, in this meta-analysis, we included more studies than before. In addition, we also used NOS to evaluate the methodological quality of the studies included, and it helped us to pick out and evaluate eligible articles.…”

Section: Discussionmentioning

confidence: 99%

“…Although there were several meta-analyses that had investigated the association, results were also inconclusive. [19–21] Therefore, in this article, we conducted a comprehensive meta-analysis from all relevant scientific literatures.…”

Section: Introductionmentioning

confidence: 99%

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Han¹,

Cao

Zhang³

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: TP53 gene polymorphism could increase risks of several kinds of cancer. But it remained controversial whether TP53 gene codon72 polymorphism was associated with the susceptibility to prostate cancer. Thus, we conducted a meta-analysis that evaluated the association between TP53 gene codon72 polymorphism and prostate cancer risk. Method: A comprehensive research was performed from PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) up to December 31, 2018. A random effect model was used to evaluate the effect of the outcome. The statistical analyses were performed with Review Manager 5.3.0 and Stata 14.0. The sensitivity analysis and publication bias tests were also performed to confirm the reliability of this meta-analysis. Results: 22 studies included 3146 cases and 4010 controls were involved in this meta-analysis. Overall, no association was observed between TP53 gene codon72 polymorphism and prostate cancer risk (Arg vs Pro: odds ratio [OR] = 1.12, 95% confidence interval [CI] = 0.98–1.30; ArgArg vs ProPro: OR = 1.26, 95% CI = 0.90–1.75; ProPro vs ArgArg+ ArgPro: OR = 1.17, 95% CI = 0.86–1.57; ArgPro+ ProPro vs ArgArg: OR = 1.21, 95% CI = 0.97–1.51). Subgroup analyses, based on ethnicity, source of control and Hardy–Weinberg equilibrium (HWE) status, showed consistent results. Conclusion: The meta-analysis we performed showed that there was no association of TP53 gene codon72 polymorphism with prostate cancer risk.

show abstract

Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta‐analysis

Cited by 6 publications

References 38 publications

Changes in TP53 gene, telomere length, mitochondrial DNA, and its amount in benign prostatic hyperplasia patients

Changes in TP53 gene, telomere length, mitochondrial DNA, and its amount in benign prostatic hyperplasia patients

IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis

Association between TP53 gene codon72 polymorphism and prostate cancer risk

Contact Info

Product

Resources

About